Sandoz wades into Humira biosimilars
Novartis's generics arm, Sandoz, is taking on AbbVie's multi-indication medication Humira. The company announced Wednesday that it had kicked off a Phase III trial of an adalimumab biosimilar. It said the trial's goal is to “demonstrate efficacy, similarity and immunogenicity of the Sandoz product versus Humira” in moderate-to-severe plaque psoriasis patients.
The division's head of biopharmaceuticals and oncology injectables, Ameet Mallik, said in a statement that the Humira biosimilar will be “a key building block in our growing immunology portfolio” and that the company has Phase III trials in effect for biologics including Amgen's Enbrel and Roche's Rituxan.